RxSight Inc. (RXST) Insider Trading

Last 12 months

Insiders sold $118k and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chief Financial Officer Mark Wilterding sold $54k on Sep 2, 24% of their stake, outside a plan. The last open-market buy by an executive or director was in Jan 2025.

Net open-market

−$118k

0 buys · 4 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

Jan 2025

Jan 16, 2025

Get an email when RXST's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 2	Ronald M Md Kurtz Chief Medical Officer	SoldNo plan	5,100	$6.96	$35k	0.6%	Form 4
Sep 2	Mark Wilterding Chief Financial Officer	SoldNo plan	7,765	$6.96	$54k	24%	Form 4
Sep 2	Ilya Goldshleger Chief Operating Officer	SoldNo plan	2,041	$6.96	$14k	2.4%	Form 4
Sep 2	Eric Weinberg See remarks	SoldNo plan	2,041	$6.96	$14k	0.4%	Form 4
Mar 12, 2025	Tamara Fountain Director	Sold10b5-1 plan	7,000	$25.71	$180k	22%	Form 4
Jan 22, 2025	Shweta Maniar Director	Sold10b5-1 plan	3,519	$30.87	$109k	32%	Form 4
Jan 15, 2025 – Jan 16, 2025	Jesse Anderson Corley Director	Bought 2 parts	3,210	$31.16 average	$100k	5.0%	Form 4
Nov 29, 2024	Ilya Goldshleger See remarks	Sold10b5-1 plan	3,105	$46.08	$143k	6.6%	Form 4
Nov 26, 2024	Shweta Maniar Director	Sold10b5-1 plan	3,782	$45.88	$174k	26%	Form 4
Nov 22, 2024 – Nov 26, 2024	Ilya Goldshleger See remarks	Sold10b5-1 plan 2 parts	6,200	$45.44 average	$282k	12%	Form 4
Nov 15, 2024 – Nov 18, 2024	Ilya Goldshleger See remarks	Sold10b5-1 plan 3 parts	7,975	$45.61 average	$364k	15%	Form 4
Nov 12, 2024 – Nov 13, 2024	Jesse Anderson Corley Director	Bought 4 parts	22,476	$45.14 average	$1.01M	4.6%	Form 4
Nov 12, 2024	Ilya Goldshleger See remarks	Sold10b5-1 plan	1,330	$46.13	$61k	3.0%	Form 4
Nov 7, 2024	Ilya Goldshleger See remarks	Sold10b5-1 plan 2 parts	3,100	$55.00 average	$170k	6.6%	Form 4
Nov 4, 2024	Ilya Goldshleger See remarks	Sold10b5-1 plan 2 parts	3,100	$51.04 average	$158k	6.6%	Form 4
Oct 30, 2024	Ilya Goldshleger See remarks	Sold10b5-1 plan	3,105	$51.91	$161k	6.6%	Form 4
Oct 25, 2024 – Oct 28, 2024	Ilya Goldshleger See remarks	Sold10b5-1 plan 2 parts	6,200	$50.22 average	$311k	12%	Form 4

Sep 2No plan
Ronald M Md Kurtz
Chief Medical Officer · sold 5,100 at $6.96
$35k
0.6% of stake
Sep 2No plan
Mark Wilterding
Chief Financial Officer · sold 7,765 at $6.96
$54k
24% of stake
Sep 2No plan
Ilya Goldshleger
Chief Operating Officer · sold 2,041 at $6.96
$14k
2.4% of stake
Sep 2No plan
Eric Weinberg
See remarks · sold 2,041 at $6.96
$14k
0.4% of stake
Mar 12, 202510b5-1 plan
Tamara Fountain
Director · sold 7,000 at $25.71
$180k
22% of stake
Jan 22, 202510b5-1 plan
Shweta Maniar
Director · sold 3,519 at $30.87
$109k
32% of stake
Jan 15, 2025 – Jan 16, 2025
Jesse Anderson Corley
Director · bought 3,210 at avg $31.16
$100k
5.0% of stake
Nov 29, 202410b5-1 plan
Ilya Goldshleger
See remarks · sold 3,105 at $46.08
$143k
6.6% of stake
Nov 26, 202410b5-1 plan
Shweta Maniar
Director · sold 3,782 at $45.88
$174k
26% of stake
Nov 22, 2024 – Nov 26, 202410b5-1 plan
Ilya Goldshleger
See remarks · sold 6,200 at avg $45.44
$282k
12% of stake
Nov 15, 2024 – Nov 18, 202410b5-1 plan
Ilya Goldshleger
See remarks · sold 7,975 at avg $45.61
$364k
15% of stake
Nov 12, 2024 – Nov 13, 2024
Jesse Anderson Corley
Director · bought 22,476 at avg $45.14
$1.01M
4.6% of stake
Nov 12, 202410b5-1 plan
Ilya Goldshleger
See remarks · sold 1,330 at $46.13
$61k
3.0% of stake
Nov 7, 202410b5-1 plan
Ilya Goldshleger
See remarks · sold 3,100 at avg $55.00
$170k
6.6% of stake
Nov 4, 202410b5-1 plan
Ilya Goldshleger
See remarks · sold 3,100 at avg $51.04
$158k
6.6% of stake
Oct 30, 202410b5-1 plan
Ilya Goldshleger
See remarks · sold 3,105 at $51.91
$161k
6.6% of stake
Oct 25, 2024 – Oct 28, 202410b5-1 plan
Ilya Goldshleger
See remarks · sold 6,200 at avg $50.22
$311k
12% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RXST, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Ophthalmic Goods

STAAStaar Surgical Company

WRBYWarby Parker Inc.

XTNTXtant Medical Holdings Inc.

INTTIntest Corporation

ANIKAnika Therapeutics Inc.

BBNXBeta Bionics Inc.

OMOutset Medical Inc.

SYPRSypris Solutions Inc.

Spot a number that looks wrong? Check it in RXST's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RXST

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.